ReviewCurrent opinion in obstetrics & gynecology2020
Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies.
Review in Current opinion in obstetrics & gynecology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 45 citations in OpenAlex.
- Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- Association of Increased MIEN1 Copy Number With Worse Outcomes in Lung Adenocarcinoma and Cervical Cancer.Cureus · 2026Article
- Trastuzumab deruxtecan (T-DXd) in HER2-expressing gynecological malignancies: Clinical evidence, safety profile, and future directions.Gynecologic oncology reports · 2026Review
- Antibody-Drug Conjugates in Gynecologic Oncology: Advances, Challenges, and Future Directions.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Molecular classification of endometrial carcinoma: clinical utility of an NGS panel with targeted detection of 116 cancer-related genes.Pathology oncology research : POR · 2026Article
- Screening, docking, and molecular dynamics analysis of Mitragyna speciosa (Korth.) compounds for targeting HER2 in breast cancer.Current research in structural biology · 2025Article
- Monotherapy and combination therapy using antibody‑drug conjugates for platinum‑resistant ovarian cancer.Oncology reports · 2025Review
- The Diverse Aspects of Uterine Serous Cancer: an NCI workshop on the status of and opportunities for advancement of research.Journal of the National Cancer Institute · 2025Article
- A single-cell network approach to decode metabolic regulation in gynecologic and breast cancers.NPJ systems biology and applications · 2025Article
- Prognostic and Predictive Roles of HER2 Status in Non-Breast and Non-Gastroesophageal Carcinomas.Cancers · 2024Review
- Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer.Journal of experimental & clinical cancer research : CR · 2024Article
- Review
- New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions.Cancer metastasis reviews · 2023Review
- Peptide Vaccines as Therapeutic and Prophylactic Agents for Female-Specific Cancers: The Current Landscape.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Review
- HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy.Gynecologic oncology · 2022Article
- Discovering Common miRNA Signatures Underlying Female-Specific Cancers via a Machine Learning Approach Driven by the Cancer Hallmark ERBB.Biomedicines · 2022Article
- CMBs carrying PTX and CRISPR/Cas9 targetingMolecular medicine reports · 2021Article
- Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives.World journal of clinical oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
purpose of reviewThe purpose of this review is to describe the role of the human epidermal growth factor receptor 2 (HER2) as a biomarker and potential target in gynecologic malignancies and to describe contemporary updates in the use of anti-HER2 treatments for these cancers. RECENT
findingsApproximately 25-30% of all patients with uterine serous carcinoma overexpress tumoral HER2. The anti-HER2 antibody trastuzumab represents an effective, targeted therapy with significant efficacy in the treatment of HER2-positive breast and gastric cancer. Recently, trastuzumab efficacy has also been demonstrated in a randomized controlled trial of women with advanced or recurrent uterine serous carcinoma. Additionally, trastuzumab may be effective in women with HER2-positive uterine carcinosarcoma. The role of anti-HER2 therapy is unclear in women with other gynecologic malignancies but is being evaluated. SUMMARY: HER2 amplification/overexpression is an effective therapeutic target in select gynecologic malignancies, and especially in the rare endometrial cancer subtype, uterine serous carcinoma. As anti-HER2-targeted therapies become increasingly available, more treatment options may become available for women with HER2-positive disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.